ORRs in B-NHL subgroups treated with loncastuximab tesirine doses 15 to 200 µg (efficacy analysis set)
| . | n (%) . | ||
|---|---|---|---|
| DLBCL (n = 137) . | MCL (n = 15) . | FL (n = 14) . | |
| ORR | 58 (42.3) | 7 (46.7) | 11 (78.6) |
| 95% CI | 33.9-51.1 | 21.3-73.4 | 49.2-95.3 |
| CR | 32 (23.4) | 5 (33.3) | 9 (64.3) |
| PR | 26 (19.0) | 2 (13.3) | 2 (14.3) |
| . | n (%) . | ||
|---|---|---|---|
| DLBCL (n = 137) . | MCL (n = 15) . | FL (n = 14) . | |
| ORR | 58 (42.3) | 7 (46.7) | 11 (78.6) |
| 95% CI | 33.9-51.1 | 21.3-73.4 | 49.2-95.3 |
| CR | 32 (23.4) | 5 (33.3) | 9 (64.3) |
| PR | 26 (19.0) | 2 (13.3) | 2 (14.3) |